Clinical trial
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent…
NCT00479817 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00479817 |
|---|---|
| Title | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer |
| Official title | A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | AMG 386, Paclitaxel, AMG 386 Placebo |
| Enrollment | 161 |
| Start date | Jul 5, 2007 |
| Primary completion | Aug 11, 2009 |
| Completion | Dec 9, 2019 |
| First posted | May 28, 2007 |
| Last update posted | Dec 18, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: